US Payers: Comparative Effectiveness Research and Formulary Decision-making
Q1, 2012
It will come as no surprise that regulatory approval is no longer the only hurdle necessary to ensure commercial success. Today, and likely more so in the future, the real hurdles will come in receiving optimal reimbursement and market access.
The question that ISR poses: How will comparative effectiveness research (CER) affect P&T Committee's reimbursement decisions?
This report was developed to answer that very question as well as some other very specific questions to US payers about comparative effectiveness research.
What you'll learn:
-
Understand how US payers define comparative effectiveness research
-
Understand the current and future influence CER study types have on formulary placement
-
Learn which CER study types are gaining importance and driving formulary decisions
-
Get a therapeutic area view of CER for the top seven therapeutic areas (Asthma/ COPD, Arthritis/ Osteoporosis, Oncology, Diabetes, Hypertension, Mental health, and Heart disease)
For more information on this report or to view the full table of contents, download our free report preview.
Similar Reports:
Purchasers of this report also purchased:
